Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...

Recursion Pharmaceuticals is trying to solve a serious problem. Even with technological improvements, the time and costs required to develop brand-new drugs have increased in recent decades. It can ...

Christopher Gibson, Co-Founder and CEO, announced, "beginning January 1, the amazing Najat Khan is going to take over the role of CEO, President and Director of Recursion." Gibson will transition to ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

The sciatic nerve is the longest and thickest nerve in your body. It's actually a bundle of five nerves that start in your lower back and run through your buttocks and down each leg. Inflammation of ...

I'm a Fitness & Nutrition writer for CNET who enjoys reviewing the latest fitness gadgets, testing out activewear and sneakers, as well as debunking wellness/fitness myths. In my free time I enjoy ...

High-impact exercises like burpees, weighted squats, cycling, and contact sports can aggravate sciatica by putting pressure on your spine, sciatic nerve, and lower back. Certain stretches and ...

Jakob Roze, CSCS, is a health writer and high-end personal trainer. He is the founder and CEO of RozeFit, a high-end concierge personal training practice and online blog. Squats train all the major ...

Correspondence to Dr Christopher James Holland, School of Sport and Exercise Science, University of Worcester, Worcester, UK; c.holland{at}worc.ac.uk In recent years, the link between physical ...

Objective To synthesise the evidence on the effects of physical activity on symptoms of depression, anxiety and psychological distress in adult populations. Design Umbrella review. Data sources Twelve ...

Recursion Pharmaceuticals to update on FDA trial design for REC-4881 for FAP in the second half of 2026. Analysts expect potential upside from rare diseases.